Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical AdvisorKetamine and Psilocybin Update in Treatment-Resistant Depression

In treatment-resistant depression, two studies found that COMP360 psilocybin therapy reduced depression and one study reported that using precision medicine for ketamine dosing might decrease the high efficacy-low effectiveness gap.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form